MBS2687

MBS2687 is a small molecule investigational drug developed by Modern Biosciences (now part of Istesso) for the treatment of immune system diseases, with a particular focus on autoimmune diseases and fibrosis. The compound is in preclinical development. While specific molecular targets are not disclosed, it is part of a pipeline that aims to modulate mitochondrial function and metabolic pathways to promote tissue repair and resolution of chronic disease processes. This approach seeks to go beyond symptom control by directly preventing or reversing tissue decline in degenerative, autoimmune, or fibrotic conditions[1][2][3].